Drug Costs
Research News and Information

Sunday, November 22, 2009

A comprehensive perspective on patient adherence to topical glaucoma therapy.

30 Oct 2009 TOPIC: Risk factors for poor adherence or nonadherence to topical glaucoma medication regimens. CLINICAL RELEVANCE: Poor adherence to glaucoma medication regimens may be associated with subsequent visual loss and irreversible optic nerve damage. ... Read more...

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

5 Oct 2009 CONTEXT: National public insurance for drugs is often based on evidence of comparative effectiveness and cost-effectiveness. This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been ... Read more...

Generic medicines: Greek physicians' perceptions and prescribing practices.

29 Sep 2009 BACKGROUND AND OBJECTIVE: The penetration of generic drugs in the Greek pharmaceutical market is placed among the weakest in the EU. The Greek regulatory framework does not systematically support the development of this subsector and physicians are ... Read more...

Latest indexed articles for 'Drug Costs'

These are the very latest articles for this heading:

• A comprehensive perspective on patient adherence to topical glaucoma therapy. 30 Oct 2009
• Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. 26 Oct 2009
• Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years. 24 Oct 2009
• Going off-label without venturing off-course: evidence and ethical off-label prescribing. 24 Oct 2009
• ASCO Rx for high drug costs: doctors and patients need to talk. 12 Oct 2009
• Cost is killing patients: subsidising effective antimalarials. 8 Oct 2009
• Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. 5 Oct 2009
• [The seemingly lethal simvastatin...] 3 Oct 2009
• Generic medicines: Greek physicians' perceptions and prescribing practices. 29 Sep 2009
• [Out-of-pocket health care expenditures among population groups in Iceland] 29 Sep 2009
• [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region] 29 Sep 2009
• Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. 23 Sep 2009
• Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. 22 Sep 2009
• Clopidogrel plus aspirin in atrial fibrillation. 22 Sep 2009
• Drugs are scarce as mix of programs aims to ease access. 13 Sep 2009
• Antiepileptic drugs in children in developing countries: research and treatment guideline needs. 8 Sep 2009
• [Clinical pharmacist in a multidisciplinary team in a paediatric department] 8 Sep 2009
• [Changing clinicians' prescription patterns] 5 Sep 2009
• Sustainability of ivermectin distribution programmes. 3 Sep 2009
• Dispelling myths about drug research. 3 Sep 2009

See a longer list of these articles.

Technical information about 'Drug Costs'

Definition: The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).

Descriptor UI: D016527

Alternative terms: Drug Costs; Cost, Drug; Costs, Drug; Drug Cost;

Allowable Qualifiers: classification; history; legislation & jurisprudence; standards; trends; statistics & numerical data; ethics;

Tree Number: N03.219.151.400.350; N05.300.375.300;

History Note: 92

Technical Notes: costs to a health care facility or organiz: do not confuse with FEES, PHARMACEUTICAL or PRESCRIPTION FEES which are costs to the patient